



Phone: (844) 598-2557 Fax: (888) 388-1309

# Soliris (Eculizumab) Prescriber Order Form

Please Fax completed form with patient's demographics, Clinical notes, and recent labs to (888) 388-1309

## PATIENT

Patient Name: \_\_\_\_\_  Male  Female SS#: \_\_\_\_\_ DOB: \_\_\_\_\_

Address: \_\_\_\_\_ City, State, Zip: \_\_\_\_\_

Primary Phone: \_\_\_\_\_  Home  Cell  Work Alternate Phone: \_\_\_\_\_  Home  Cell  Work

Email: \_\_\_\_\_

Allergies: \_\_\_\_\_

## Clinical Information

Patient's Weight: \_\_\_\_\_ Lbs (Required)

Diagnosis:  Paroxysmal nocturnal hemoglobinuria (PNH) (ICD-10 Code: D59.5)  Neuromyelitis Optica Spectrum disorders (NMOSD) (ICD-10 Code: G36.0)  
 Atypical hemolytic uremic syndrome (aHUS) (ICD-10 Code: D59.3)  Other: \_\_\_\_\_ (ICD-10 Code: \_\_\_\_\_)  
 Myasthenia Gravis w/out acute exacerbation (gMG) (ICD-10 Code: G70.00)  
Myasthenia Classification:  II  III  IV

## Soliris Prescription Order (Prescriber MUST be enrolled in Soliris REMS)

### Soliris Adult Dosing:

#### PNH Diagnosis

- Initial Start: 600mg IV weekly for the first 4 weeks, followed by 900mg IV for the fifth dose 1 week later, then 900mg IV every 2 weeks thereafter x 1 year
- Maintenance Dose: 900mg IV every 2 weeks x 1 year

#### aHUS, gMG, and NMOSD Diagnosis

- Initial dose: 900mg IV weekly for the first 4 weeks, followed by 1200mg IV for the fifth dose 1 week later, then 1200mg IV every 2 weeks thereafter x 1 year
- Maintenance Dose: 1200mg IV every 2 weeks x 1 year

## Ancillary Orders

**Anaphylaxis Kit** If this is a 1<sup>st</sup> infusion dose, would you like SandsRx Pharmacy to provide an anaphylaxis kit with the 1<sup>st</sup> dose?  
 Yes  No

- Dosage:**
- Give Diphenhydramine capsule (s) 25 mg to 50 mg PO as needed **#4 capsules**
  - Epinephrine 0.3 mg (> 30 kg), 0.15 mg (15 to 30 kg), or 0.01 mg/kg (< 15 kg) SQ or IM x 1; repeat x 1 in 5 to 15 min PRN. **#2 vials**
  - Diphenhydramine 25 mg (> 30 kg) or 1.25 mg/kg (≤ 30 kg) IV or IM; repeat x 1 in 15 min PRN no improvement. **#1 vial**
  - Normal saline 500 mL (> 30 kg) or 250 mL (≤ 30 kg) IV at KVO rate PRN anaphylaxis. Patients ≤ 30 kg, infuse over 2 to 4 hours PRN headache rated > 5 on pain scale.

#### Pre- Medication Orders

- Acetaminophen 650 mg PO 30 min before infusion, may repeat every 3 to 4 hours as needed for fever or mild discomfort. Patient may decline.
- Diphenhydramine 25 mg PO 30 min before infusion, may repeat every 4 to 6 hours as needed for mild to moderate allergic reactions. Patient may decline.
- Loratadine 10 mg PO 30 min before infusion. Patient may decline.
- Methylprednisolone Succinate \_\_\_\_\_ mg IV push 20 minutes prior to infusion.
- Other: \_\_\_\_\_

#### IV Flush Orders

- Peripheral: NS 2 to 3 mL pre-/post-use.
- Implanted Port: NS 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use. For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed or weekly to monthly if not accessed.

#### Lab Orders

- No labs ordered at this time.
- Other: \_\_\_\_\_

Skilled Nursing Visits: As needed for IV access, administration and appropriate clinical monitoring. Administration procedures to be followed per protocol. Pump and supplies as needed for administration and appropriate disposal of infusion materials. Refill above ancillary orders as directed x 1 year.

*I certify that the use of the indicated treatment is medically necessary and I will be supervising the patient's treatment.*

Prescriber Signature: \_\_\_\_\_

Date: \_\_\_\_\_

## Prescriber Information

Prescriber Name:	Phone:	Fax:
Address:	NPI:	
City, State:	Zip:	Office Contact:

**CONFIDENTIAL HEALTH INFORMATION:** Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. **IMPORTANT WARNING:** This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.